Literature DB >> 7538851

Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients.

M Weiss1, W Gross-Weege, M Schneider, H Neidhardt, S Liebert, N Mirow, P Wernet.   

Abstract

PURPOSE: To determine the kinetics of leukocyte counts and of oxygen radical production of neutrophils from postoperative/posttraumatic patients with or without infusion of filgrastim (recombinant human granulocyte colony-stimulating factor, rhG-CSF) as prophylaxis against sepsis.
METHODS: Twenty postoperative/posttraumatic patients with a Therapeutic Intervention Scoring System (TISS) score greater than 30 were included in this study. In the 10 patients of the study group, filgrastim (1 microgram/kg/d) was infused continuously within the first 3 days and tapered to 0.5 microgram/kg/d on the following 4 days or until discharge from the surgical intensive care unit. Ten patients without administration of filgrastim served as controls. Oxygen radical production of isolated neutrophils of these patients was tested by N-formyl-methionyl-leucyl-phenylalanine (FMLP)- and zymosan-induced chemiluminescence from serial blood samples, taken until the 16th postoperative day.
RESULTS: Compared with the first postoperative day, in vitro FMLP-induced neutrophil chemiluminescence was significantly increased during the following 4 postoperative days in the patients with filgrastim infusion; however, only during the first 2 postoperative days in the control group. The increase in the FMLP-induced neutrophil chemiluminescence was significantly greater (P < .05) in the study group than in the control group on the third and on the fourth postoperative day. Tapering of filgrastim by 0.5 microgram/kg/d in the study group resulted in a reduction of FMLP-induced neutrophil oxygen radical production within 48 hours. In contrast, zymosan-induced neutrophil chemiluminescence was not measurably affected in both groups. Leukocyte count of the study group significantly (P < .05) exceeded the leukocyte count of the control group from the third up to the 10th postoperative day. None of the patients treated with filgrastim developed sepsis; however, three patients within the control group did.
CONCLUSIONS: Prolonged enhancement of neutrophil count and function induced by rhG-CSF may be useful in the prophylaxis of sepsis in posttraumatic/postoperative patients at high risk of sepsis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538851     DOI: 10.1016/0883-9441(95)90027-6

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  9 in total

1.  Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.

Authors:  Manfred Weiss; Sami Voglic; Britt Harms-Schirra; Ingrid Lorenz; Britta Lasch; Kristoffel Dumon; Wilhelm Gross-Weege; Elisabeth Marion Schneider
Journal:  Intensive Care Med       Date:  2003-04-08       Impact factor: 17.440

2.  Granulocyte colony-stimulating factor (G-CSF) serum levels in surgical intensive care patients.

Authors:  W Gross-Weege; K Dumon; A Dahmen; E M Schneider; H D Röher
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

3.  Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.

Authors:  Christian Schneider; Sonja von Aulock; Siegfried Zedler; Christian Schinkel; Thomas Hartung; Eugen Faist
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

4.  Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis.

Authors:  Artur Bauhofer; Alexander Torossian; Wilfried Lorenz; Martin Middeke; Ulrike Plaul; Philipp Schütz; Benno Stinner; Markus Hattel; Ilhan Celik
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

5.  Effects of granulocyte-colony stimulating factor on the polymorphonuclear leukocyte activity and the course of sepsis in rats with experimental peritonitis.

Authors:  Gunay Gurleyik; Gulderen Yanikkaya; Emin Gurleyik; Erol Ozturk; Ender Dulundu; Abdullah Saglam
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

6.  Differential effects of antibiotics in combination with G-CSF on survival and polymorphonuclear granulocyte cell functions in septic rats.

Authors:  Artur Bauhofer; Markus Huttel; Wilfried Lorenz; Daniel I Sessler; Alexander Torossian
Journal:  BMC Infect Dis       Date:  2008-04-30       Impact factor: 3.090

Review 7.  The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

Authors:  Jonathan S Boomer; Jonathan M Green; Richard S Hotchkiss
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

8.  Preferential production of G-CSF by a protein-like Lactobacillus rhamnosus GR-1 secretory factor through activating TLR2-dependent signaling events without activation of JNKs.

Authors:  Shahab Meshkibaf; Jӧrg Fritz; Marcelo Gottschalk; Sung Ouk Kim
Journal:  BMC Microbiol       Date:  2015-10-26       Impact factor: 3.605

Review 9.  Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Authors:  Elie Azoulay; Christophe Delclaux
Journal:  Intensive Care Med       Date:  2003-10-31       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.